Treatment Study of Intracranial Dural Arteriovenous Fistulas

Clinical Trial Title

PHIL dAVF: Study of Phil® Embolic System in the treatment of intracranial dural arteriovenous fistulas.

Clinical Trial Protocol Description:

This study is a prospective, multicenter, single-arm study. Patients with dural arteriovenous fistulas (dAVF) have a few choices for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are between 22 and 80 years of age.
  • Are willing and capable of complying with all study protocol requirements, including specified follow-up period.
  • Provide written informed consent (subject or authorized legal representative) prior to initiation of any study procedures.
  • Have an intracranial dAVF.

You will be excluded from the study if any of the following criteria apply to you:

  • Have multiple dAVFs to be treated.
  • Have a history of life threatening allergy to contrast media (unless treatment for allergy is tolerated).
  • Have known allergies to dimethylsulfoxide, iodine.
  • Are currently participating in another clinical study

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Michael Chen, MD

Contact Information

Kevin Keegan

(312) 942-8681